Assets
+ PerkinElmer
History
2021: Purchase of a developer and manufacturer of antibodies and reagents BioLegend
At the end of September 2021, PerkinElmer announced the completion of the acquisition of the developer and manufacturer of antibodies and reagents used in biomedical research - the company BioLegend - for $5.25 billion. More details here.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |